Ebos Group Ltd (ASX: EBO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Ebos Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$4.39 billion
P/E Ratio
21.52
Dividend Yield
4.36%
Shares Outstanding
203.26 million
Earnings per share
1.174
Dividend per share
0.98
Year To Date Return
-7.70%
Earnings Yield
4.65%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Ebos Group Ltd (ASX: EBO)
Latest News
Investing Strategies
'Stock is oversold': 5 ASX shares to buy now before resurgence
Earnings Results
3 ASX 300 shares going gangbusters on stellar earnings results
Share Fallers
Why ASX, Baby Bunting, Bowen Coking Coal, and EBOS shares are sinking today
Broker Notes
7 more ideas for buying ASX shares this reporting season: expert
52-Week Highs
5 ASX All Ords shares cracking new 52-week highs on Tuesday
Share Market News
5 profitable ASX shares you probably have never heard of
Healthcare Shares
This ASX All Ordinaries share shrugged off the red to reach a new 52-week high today
Earnings Results
Here are 3 ASX healthcare share results you might have missed
Share Market News
Here are the top 10 ASX shares today
Broker Notes
Why this $7 billion ASX-listed company is a 'hidden gem': expert
Capital Raising
Here's why the EBOS (ASX:EBO) share price is climbing today
Mergers & Acquisitions
EBOS (ASX:EBO) share price on watch amid cap raise and $1 billion acquisition
Frequently Asked Questions
-
Yes, EBOS Group has historically paid two partially franked shareholder dividends a year.
-
EBOS Group generally pays its shareholder dividends in March and September.
-
Yes, EBOS has a dividend reinvestment plan to allow shareholders to reinvest all or part of their dividends.
-
EBOS Group Ltd listed on the ASX on 6 September 2013.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 04 Sep 2025 | $0.6150 | 0.00% | Final | 24 Sep 2025 |
| 27 Feb 2025 | $0.0251 | 0.00% | Supplemental | 21 Mar 2025 |
| 29 Aug 2024 | $0.5043 | 0.00% | Final | 18 Sep 2024 |
| 29 Feb 2024 | $0.1510 | 0.00% | Supplemental | 22 Mar 2024 |
| 07 Sep 2023 | $0.0251 | 0.00% | Supplemental | 29 Sep 2023 |
| 07 Sep 2023 | $0.4705 | 0.00% | Final | 29 Sep 2023 |
| 02 Mar 2023 | $0.0234 | 0.00% | Supplemental | 17 Mar 2023 |
| 02 Mar 2023 | $0.4259 | 0.00% | Interim | 17 Mar 2023 |
| 08 Sep 2022 | $0.0216 | 0.00% | Supplemental | 30 Sep 2022 |
| 08 Sep 2022 | $0.3800 | 0.00% | Final | 30 Sep 2022 |
| 03 Mar 2022 | $0.0207 | 0.00% | Supplemental | 18 Mar 2022 |
| 03 Mar 2022 | $0.3917 | 0.00% | Interim | 18 Mar 2022 |
| 09 Sep 2021 | $0.0203 | 0.00% | Supplemental | 24 Sep 2021 |
| 09 Sep 2021 | $0.3953 | 0.00% | Final | 24 Sep 2021 |
| 04 Mar 2021 | $0.0188 | 0.00% | Supplemental | 18 Mar 2021 |
| 04 Mar 2021 | $0.3506 | 0.00% | Interim | 18 Mar 2021 |
| 24 Sep 2020 | $0.0176 | 0.00% | Supplemental | 09 Oct 2020 |
| 24 Sep 2020 | $0.3289 | 0.00% | Final | 09 Oct 2020 |
| 12 Mar 2020 | $0.0165 | 0.00% | Supplemental | 03 Apr 2020 |
| 12 Mar 2020 | $0.3232 | 0.00% | Interim | 03 Apr 2020 |
| 26 Sep 2019 | $0.0163 | 0.00% | Supplemental | 11 Oct 2019 |
| 26 Sep 2019 | $0.3076 | 0.00% | Final | 11 Oct 2019 |
| 14 Mar 2019 | $0.0152 | 0.00% | Supplemental | 05 Apr 2019 |
| 14 Mar 2019 | $0.2920 | 0.00% | Interim | 05 Apr 2019 |
| 27 Sep 2018 | $0.2871 | 0.00% | Final | 12 Oct 2018 |
| 15 Mar 2018 | $0.0146 | 0.00% | Supplemental | 06 Apr 2018 |
| 15 Mar 2018 | $0.2766 | 0.00% | Interim | 06 Apr 2018 |
| 28 Sep 2017 | $0.0146 | 0.00% | Supplemental | 13 Oct 2017 |
| 28 Sep 2017 | $0.2664 | 0.00% | Final | 13 Oct 2017 |
| 16 Mar 2017 | $0.2453 | 0.00% | Interim | 07 Apr 2017 |
| 29 Sep 2016 | $0.2697 | 0.00% | Final | 14 Oct 2016 |
| 10 Mar 2016 | $0.2075 | 0.00% | Interim | 01 Apr 2016 |
| 30 Sep 2015 | $0.2024 | 0.00% | Final | 16 Oct 2015 |
| 11 Mar 2015 | $0.1884 | 0.00% | Interim | 02 Apr 2015 |
| 01 Oct 2014 | $0.1650 | 0.00% | Final | 17 Oct 2014 |
| 12 Mar 2014 | $0.1776 | 0.00% | Interim | 04 Apr 2014 |
| 06 Apr 2011 | $0.1350 | 0.00% | Interim | 21 Apr 2011 |
| 08 Sep 2010 | $0.1750 | 0.00% | Final | 08 Oct 2010 |
| 15 Mar 2010 | $0.1350 | 0.00% | Interim | 13 Apr 2010 |
| 07 Sep 2009 | $0.1450 | 0.00% | Final | 02 Oct 2009 |
| 23 Mar 2009 | $0.1050 | 0.00% | Interim | 21 Apr 2009 |
| 15 Sep 2008 | $0.0238 | 0.00% | Supplemental | 10 Oct 2008 |
| 15 Sep 2008 | $0.1350 | 0.00% | Final | 10 Oct 2008 |
| 14 Apr 2008 | $0.0168 | 0.00% | Supplemental | 09 May 2008 |
| 14 Apr 2008 | $0.0950 | 0.00% | Interim | 09 May 2008 |
| 23 Oct 2007 | $0.0229 | 0.00% | Supplemental | 26 Oct 2007 |
| 23 Oct 2007 | $0.1300 | 0.00% | Final | 26 Oct 2007 |
| 16 Apr 2007 | $0.0168 | 0.00% | Supplemental | 20 Apr 2007 |
| 16 Apr 2007 | $0.0950 | 0.00% | Interim | 20 Apr 2007 |
| 24 Oct 2006 | $0.0229 | 0.00% | Supplemental | 27 Oct 2006 |
| 24 Oct 2006 | $0.1300 | 0.00% | Final | 27 Oct 2006 |
| 03 Apr 2006 | $0.0168 | 0.00% | Supplemental | 07 Apr 2006 |
| 03 Apr 2006 | $0.0950 | 0.00% | Interim | 07 Apr 2006 |
| 03 Oct 2005 | $0.0221 | 0.00% | Supplemental | 07 Oct 2005 |
| 03 Oct 2005 | $0.1250 | 0.00% | Final | 07 Oct 2005 |
| 14 Mar 2005 | $0.0159 | 0.00% | Supplemental | 18 Mar 2005 |
| 14 Mar 2005 | $0.0900 | 0.00% | Interim | 18 Mar 2005 |
EBO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Ebos Group Ltd
EBOS Group Ltd (ASX: EBO) is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, public and private hospitals, day surgeries, general practices, aged care facilities, and specialist clinics.
EBOS Group also operates an animal health product wholesale, manufacturing, and retail business, as well as providing third-party logistics services.
The vast majority of the company's revenue derives from its services to community pharmacies and institutional healthcare providers, which accounts for about 80% of revenue. Its Australian operations similarly contribute around 80% of its total revenue.
EBO Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 Feb 2026 | $22.15 | $0.33 | 1.51% | 83,727 | $21.95 | $22.38 | $21.82 |
| 04 Feb 2026 | $21.82 | $-0.03 | -0.14% | 114,831 | $21.81 | $22.09 | $21.61 |
| 03 Feb 2026 | $21.85 | $-0.56 | -2.50% | 130,944 | $23.08 | $23.08 | $21.74 |
| 02 Feb 2026 | $22.41 | $0.31 | 1.40% | 60,096 | $21.85 | $22.43 | $21.85 |
| 30 Jan 2026 | $22.10 | $0.40 | 1.84% | 89,688 | $22.55 | $22.55 | $21.87 |
| 29 Jan 2026 | $21.70 | $-0.44 | -1.99% | 238,141 | $22.00 | $22.25 | $21.63 |
| 28 Jan 2026 | $22.14 | $-0.77 | -3.36% | 122,177 | $22.89 | $23.05 | $22.03 |
| 27 Jan 2026 | $22.91 | $0.07 | 0.31% | 175,127 | $23.00 | $23.26 | $22.72 |
| 23 Jan 2026 | $22.84 | $0.13 | 0.57% | 167,231 | $22.75 | $23.09 | $22.75 |
| 22 Jan 2026 | $22.71 | $0.17 | 0.75% | 233,568 | $22.42 | $22.91 | $22.42 |
| 21 Jan 2026 | $22.54 | $-0.05 | -0.22% | 61,686 | $22.87 | $22.87 | $22.49 |
| 20 Jan 2026 | $22.59 | $-0.16 | -0.70% | 95,308 | $22.40 | $22.74 | $22.36 |
| 19 Jan 2026 | $22.75 | $0.05 | 0.22% | 102,175 | $22.70 | $22.75 | $22.30 |
| 16 Jan 2026 | $22.70 | $0.13 | 0.58% | 107,906 | $22.50 | $22.88 | $22.45 |
| 15 Jan 2026 | $22.57 | $0.03 | 0.13% | 83,844 | $22.51 | $22.70 | $22.28 |
| 14 Jan 2026 | $22.54 | $-0.14 | -0.62% | 375,981 | $23.00 | $23.00 | $22.54 |
| 13 Jan 2026 | $22.68 | $-0.82 | -3.49% | 160,619 | $23.50 | $23.63 | $22.68 |
| 12 Jan 2026 | $23.50 | $0.06 | 0.26% | 62,786 | $23.44 | $23.74 | $23.42 |
| 09 Jan 2026 | $23.44 | $-0.04 | -0.17% | 71,826 | $23.60 | $23.73 | $23.39 |
| 08 Jan 2026 | $23.48 | $-0.15 | -0.63% | 51,684 | $23.43 | $23.85 | $23.43 |
| 07 Jan 2026 | $23.63 | $0.04 | 0.17% | 94,403 | $23.59 | $24.09 | $23.59 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Dec 2025 | Coline McConville | Buy | 1,000 | $24,347 |
On-market trade.
|
| 27 Nov 2025 | Julie Tay | Buy | 1,000 | $28,000 |
On-market trade. NZ$
|
| 10 Nov 2025 | Matthew Muscio | Buy | 3,800 | $108,563 |
On-market trade. NZ$
|
| 30 Oct 2025 | Tracey Batten | Buy | 2,728 | $67,531 |
On-market trade.
|
| 21 Oct 2025 | Mark Bloom | Buy | 1,500 | $37,647 |
On-market trade.
|
| 07 Oct 2025 | Julie Tay | Buy | 2,000 | $52,000 |
On-market trade.
|
| 24 Sep 2025 | Stuart McLauchlan | Issued | 56 | $1,623 |
Dividend Reinvestment Plan (DRP). NZ$
|
| 23 Sep 2025 | Elizabeth(Liz) Coutts | Buy | 3,000 | $87,903 |
On-market trade. NZ$
|
| 22 Sep 2025 | Stuart McLauchlan | Buy | 1,000 | $29,200 |
On-market trade. NZ$
|
| 04 Sep 2025 | Matthew Muscio | Expiry | 15,828 | $443,975 |
As advised by the company. Lapse of performance rights
17,859 performance rights |
| 30 May 2025 | Mark Bloom | Buy | 2,000 | $68,800 |
On-market trade.
|
| 13 May 2025 | Elizabeth(Liz) Coutts | Issued | 1,364 | $49,990 |
Issue of securities. NZ$, retail offer
|
| 13 May 2025 | Stuart McLauchlan | Issued | 95 | $3,481 |
Issue of securities. NZ$, retail offer
|
| 13 May 2025 | Tracey Batten | Issued | 272 | $9,968 |
Issue of securities. NZ$ retail offer
|
| 21 Mar 2025 | Stuart McLauchlan | Issued | 39 | $1,442 |
Dividend Reinvestment Plan (DRP). NZ$
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Elizabeth(Liz) Mary Coutts | Non-Executive DirectorNon-Executive Chairman | Nov 2013 |
Ms Coutts is a former Chair of Skellerup Holdings Limited, Ports of Auckland Limited, Meritec Group, Industrial Research, Life Pharmacy Limited, former director of Air New Zealand Limited, the Health Funding Authority, Sanford Limited, the Yellow Group of Companies and Tennis Auckland Region Incorporated, former Deputy Chairman of Public Trust, former board member of Sport NZ, former member of the Pharmaceutical Management Agency (Pharmac) and Marsh New Zealand Advisory Board, former Commissioner for both the Commerce and Earthquake Commissions, former external monetary policy adviser to the Governor of the Reserve Bank of New Zealand, a former president of the Institute of Directors Inc and former Chief Executive of the Caxton Group of Companies. She is a member of the Risk Committee.
|
| Mr Mark Alan Bloom | Non-Executive Director | Sep 2022 |
Mr Bloom is a former director of Pacific Smiles Group Limited and Abacus Property Group. Mark has over 35 years of experience as a finance executive. Prior to this, he was Deputy Group CFO of Westfield Group for 11 years. Mark has also held several senior finance roles, including being CFO and executive director for insurance and financial services companies Liberty Life, South Africa and Manulife Financial, Canada. Mark is a member of the Audit and Risk Committee.
|
| Mr Stuart McLauchlan | Non-Executive Director | Jul 2019 |
Mr McLauchlan is a partner of GS McLauchlan & Co. He is currently chairman of Scott Technology Ltd, ADInstruments Ltd, Cargill Hotel 2022 Ltd, Otago Community Hospice and Woods Solutions. He is the director of Argosy Properties Ltd and Scenic Hotels Group, as as several private companies. He is also a governor of the New Zealand Sports Hall of Fame. He was formerly a chairman of Pharmac and UDC Finance, member of the Marsh New Zealand Advisory Board, and director of Ngai Tahu Tourism Ltd. He is Chairman of the Risk Committee.
|
| Mr Matthew Peter Muscio | Non-Executive Director | Jan 2025 |
Mr Muscio's career spans more than 25 years in the medical device industry with the last 15 years in medical technology distribution under both public and private ownership models. Matt has been a board member for the Medical Technology Association of Australia from 2017 to 2023 and currently serves as a non-executive board member for Tetrous Inc, a regenerative medicine company.
|
| Dr Tracey Leigh Batten | Non-Executive Director | Jul 2021 |
Dr Batten is currently a non-executive director of Medibank Private Limited and Nanosonics Limited. She was previously Chair of the Accident Compensation Corporation, a non-executive director of National Institute of Water and Atmospheric Research, Abano Healthcare Group Limited and various other healthcare related research institutes, charities and industry and government bodies. During her executive career she was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent's Health Australia, CEO of Eastern Health and CEO of Dental Health Services Victoria. Mark is a member of the Risk Committee.
|
| Ms Julie Tay | Non-Executive Director | May 2023 |
Ms Tay is currently a director of Sonova, a global hearing care solutions company, headquartered in Switzerland and listed on the Swiss stock exchange. She has over 30 years of experience in international executive and non-executive roles across consumer healthcare, medical devices and digital healthcare. Julie was most recently Senior Vice President and Managing Director, Asia Pacific and member of the global Executive Management Committee for Align Technology. Prior to this, she was regional head of Bayer Healthcare (Diabetes Care) in Asia Pacific and previously held senior executive roles in Asia at Johnson Diversey and Johnson & Johnson.
|
| Ms Coline McConville | Non-Executive Director | Feb 2025 |
Ms McConville has 20 years of governance experience advising a range of organizations operating in different countries and industries. Her expertise includes advising across acquisitive portfolio companies, complex distribution organizations, capital intensive businesses, consumer driven vertically integrated and global service companies. During her executive career, Ms McConville was Chief Executive Officer and Chief Operating Officer for Clear Channel Communications (now iHeartMedia Inc.) and a management consultant with McKinsey and Co and LEK Consulting. She is currently a director of 3i Group and a member of the Supervisory Board of Germany-based Tui AG. Her previous directorships include Kings Cross Central General Partnership, TUI Travel, UTV Media, Travis Perkins, Fevertree Drinks, Inchcape, Wembley National Stadium, Shed Media, Halifax and HBOS.
|
| Grant Viney | CEO Animal Care |
-
|
|
| Kristine James | CEO Medical Technology |
-
|
|
| Brett Barons | CEO Symbion & Healthcare Distribution |
-
|
|
| Alistair Gray | Chief Financial Officer |
-
|
|
| Mithran Naiker | Chief Information Officer |
-
|
|
| Martin Krauskopf | Chief Strategy and Corporate Development Officer |
-
|
|
| David Lewis | EGM |
-
|
|
| Simon Bunde | EGM Strategic Operations ESG and Innovation |
-
|
|
| Jacinta McCarthy | Executive General Manager Human Resources |
-
|
|
| Janelle Cain | General Counsel |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| JP Morgan Nominees Australia Limited | 25,085,843 | 12.34% |
| HSBC Nominees (New Zealand) Limited NZCSD | 14,677,082 | 7.22% |
| HSBC Custody Nominees (Australia) Limited | 13,682,865 | 6.73% |
| BNP Paribas Nominees (NZ) Limited NZCSD | 13,500,892 | 6.64% |
| Custodial Services Limited | 12,678,532 | 6.24% |
| Sybos Holdings PTE Limited | 9,957,825 | 4.90% |
| Forsyth Barr Custodians Limited | 8,616,830 | 4.24% |
| HSBC Nominees (New Zealand) Limited A/C State Street NZCSD | 8,506,099 | 4.19% |
| Tea Custodians Limited Client Property Trust Account NZCSD | 8,317,469 | 4.09% |
| JPMorgan Chase Bank NA NZ Branch-Segregated Clients Acct NZCSD | 7,772,261 | 3.82% |
| Citibank Nominees (New Zealand) Limited NZCSD | 7,202,785 | 3.54% |
| Accident Compensation Corporation NZCSD | 6,391,154 | 3.15% |
| HSBC Nominees A/C NZ Superannuation Fund Nominees Limited NZCSD | 5,480,889 | 2.70% |
| FNZ Custodians Limited | 4,197,368 | 2.07% |
| JBWere (NZ) Nominees Limited | 2,804,413 | 1.38% |
| ANZ Wholesale Australasian Share Fund NZCSD | 2,655,236 | 1.31% |
| Citicorp Nominees Pty Limited | 2,612,454 | 1.29% |
| New Zealand Depository Nominee Limited | 2,499,353 | 1.23% |
| Generate Kiwisaver Public Trust Nominees Limited <NZCSD> | 2,020,090 | 0.99% |
| Simplicity Nominees Limited NZCSD | 1,862,793 | 0.91% |
